Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Uveal Melanoma 1Oligodendroglioma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × NSC 366140 × Clear all
NCT00003714 2012-02-22

Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡